Try our Advanced Search for more refined results

BURLINGTON DRUG CO., INC. et al v. PFIZER INC. et al

Track this case

Case overview

Case Number:

3:12-cv-02389

Court:

New Jersey

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Zahid N. Quraishi

Firms

Companies

Sectors & Industries:

  1. August 21, 2020

    Berger Montague Drops Bankrupt Client In Lipitor Case

    Berger Montague agreed to drop its representation of Rochester Drug Cooperative Inc. in antitrust litigation over the cholesterol drug Lipitor, following another drug wholesaler's assertion that Rochester's recently filed bankruptcy creates potential conflicts in the long-running case.

  2. July 10, 2019

    Disciplinary Action Omission Prompts Atty Admission Redo

    The normally mundane process of admitting outside attorneys to participate in specific litigation in a jurisdiction to which they are not admitted got complicated for a prominent antitrust plaintiff's bar attorney who initially failed to report years-old disciplinary actions in his application to participate in a New Jersey case.

  3. August 22, 2018

    Pfizer Chips Away At State Claims In Lipitor Antitrust MDL

    A New Jersey federal judge has found that state antitrust claims against Pfizer Inc. and Ranbaxy Inc. tied to sales of the blockbuster cholesterol medication Lipitor aren't preempted by federal patent law, but that several antitrust and consumer protection claims can be cut on other grounds.

  4. May 15, 2018

    3rd Circ. Already OK'd Lipitor State Claims, Health Plans Say

    The Third Circuit has already cleared a group of health plans that paid for the blockbuster cholesterol medication Lipitor to bring antitrust litigation against Pfizer Inc. and Ranbaxy Inc. based on various state laws, so the drugmakers' bid to dismiss the claims is fruitless, the plans told a New Jersey federal court Monday.

  5. April 17, 2018

    Pfizer, Ranbaxy Look To Dump State Claims In Lipitor MDL

    Pfizer Inc. and generic-drug maker Ranbaxy Inc. asked a New Jersey federal court Monday to quash state law claims in multidistrict litigation from a group of Lipitor buyers that say the companies participated in an illegal pay-for-delay scheme to keep a generic version of the cholesterol drug out of the market.

  6. March 17, 2015

    Lipitor Buyers Can't Update Pay-For-Delay Suit Again

    A New Jersey judge refused Monday to let Lipitor purchasers once again amend their complaint accusing Pfizer Inc. of paying off Ranbaxy Laboratories Ltd. through a patent settlement to delay launching a generic version of the cholesterol drug.

  7. October 31, 2014

    Pfizer Ducks End-Payors' Lipitor Antitrust Claims

    A New Jersey federal judge on Thursday dismissed antitrust claims brought by indirect buyers of Lipitor in multidistrict litigation alleging Pfizer Inc. and Ranbaxy Laboratories Ltd. entered an anti-competitive patent infringement settlement, ruling the buyers' suit, like a previously dismissed direct-purchaser suit, fails to state a claim.

  8. October 28, 2014

    Pfizer Says Lipitor Buyers Shouldn't Get To Redo Antitrust Suit

    Pfizer Inc. and Ranbaxy Laboratories Ltd. urged a New Jersey federal court Monday to reject a bid by Lipitor purchasers to revive a pay-for-delay antitrust case over a patent settlement for the cholesterol drug, saying the buyers didn't deserve a fourth shot at the case.

  9. September 29, 2014

    Lipitor Plaintiffs Admit Pay-For-Delay Suit Doomed

    Indirect purchasers of Lipitor on Friday admitted that a New Jersey federal judge's dismissal of a similar direct-purchaser action dooms their antitrust suit in a multidistrict litigation challenging an allegedly anti-competitive patent infringement settlement between Pfizer Inc. and Ranbaxy Laboratories Ltd.

  10. September 22, 2014

    Pfizer Pushes To Ax Rest Of Lipitor Pay-For-Delay Suit

    Pfizer Inc. and Ranbaxy Laboratories Ltd. urged a New Jersey federal judge on Friday to toss indirect purchasers' antitrust suit in multidistrict litigation challenging a purportedly anti-competitive patent infringement settlement between the companies over Lipitor, saying the claims were doomed after a similar direct purchaser action was recently dismissed.